Bayer AG announced Friday a $2.2 billion investment in a new pharmaceutical manufacturing site in New Albany, Ohio, creating 600 permanent plant jobs and 1,500 construction positions.
The facility will combine drug substance and drug product manufacturing with advanced digital and automation technologies to support Bayer's oncology, cardiovascular and renal care portfolios. The first manufacturing module is scheduled to begin operations in 2031, with a second module coming online in 2034.
Bayer CEO Bill Anderson said the plant will combine "manufacturing expertise with a skilled workforce, enhancing Bayer's capacity to deliver innovative, high-quality medicines to patients across the United States and worldwide."
Ohio's workforce development infrastructure sealed the deal. The Ohio Life Science Training Center, under construction and set to open in summer 2027, will train biomanufacturing operators and technicians. JobsOhio, New Albany and The New Albany Company are jointly investing over $30 million in the facility.
Bayer is pursuing a Job Creation Tax Credit from Ohio's Department of Development and support from JobsOhio. Details of state assistance will be finalized once agreements are executed.
The investment expands Bayer's U.S. manufacturing footprint beyond existing sites in Pittsburgh, Berkeley, Cambridge, North Carolina and San Diego. For equity holders, this represents a material capital commitment to domestic production capacity—with full ramp not expected until 2034—and signals confidence in the company's growth trajectory in key therapeutic areas.
